What question did this study set out to answer?

To characterize the real-world treatment practices for Guillain-Barré syndrome across various disease severities, treatment responses, and clinical variants.

June 8, 2019ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Current treatment practice of Guillain-Barré syndrome

View Full Paper

Ask AI

Bookmark

Authors

CVChristine VerboonErasmus MC ADAlex Y. DoetsLeiden University GGGiuliana GalassiUniversity of Modena and Reggio Emilia

Discussion

Member takes

Implication

Prospective cohort study reveals frequent immunotherapy use in mild and variant Guillain-Barré syndrome, highlighting a gap between clinical practice and evidence-based guidelines.

Key Points

To characterize the real-world treatment practices for Guillain-Barré syndrome across various disease severities, treatment responses, and clinical variants.
Analyzed prospective observational data from the first 1,300 patients enrolled in the International GBS Outcome Study.
Evaluated the use of intravenous immunoglobulin, plasma exchange, and other immunotherapies across patient subgroups, excluding 88 patients due to missing data or alternative diagnoses and analyzing 189 patients from Bangladesh separately.
Immunotherapy was administered to 92% (941/1,023) of patients outside Bangladesh, including 97% (724/743) with severe disease, 75% (126/168) with mild disease, and 76% (53/70) with Miller Fisher syndrome.
Among 235 patients with no improvement following initial treatment, 35% (82/235) received a second course of immunomodulatory therapy.
Treatment-related fluctuations occurred in 5% (53/1,023) of patients, of whom 68% (36/53) underwent re-treatment with intravenous immunoglobulin or plasma exchange.

Cite This Study

Verboon et al. (2019) studied this question.

synapsesocial.com/papers/6a747518f2cd31a1fadbd4fc https://doi.org/10.1212/wnl.0000000000007719

View Full Paper

Ask AI

Bookmark

June 8, 2019ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)Open Access

Current treatment practice of Guillain-Barré syndrome

View Full Paper

Ask AI

Bookmark

Authors

CVChristine VerboonErasmus MC ADAlex Y. DoetsLeiden University GGGiuliana GalassiUniversity of Modena and Reggio Emilia

Discussion

Member takes

Implication

Prospective cohort study reveals frequent immunotherapy use in mild and variant Guillain-Barré syndrome, highlighting a gap between clinical practice and evidence-based guidelines.

Key Points

To characterize the real-world treatment practices for Guillain-Barré syndrome across various disease severities, treatment responses, and clinical variants.
Analyzed prospective observational data from the first 1,300 patients enrolled in the International GBS Outcome Study.
Evaluated the use of intravenous immunoglobulin, plasma exchange, and other immunotherapies across patient subgroups, excluding 88 patients due to missing data or alternative diagnoses and analyzing 189 patients from Bangladesh separately.
Immunotherapy was administered to 92% (941/1,023) of patients outside Bangladesh, including 97% (724/743) with severe disease, 75% (126/168) with mild disease, and 76% (53/70) with Miller Fisher syndrome.
Among 235 patients with no improvement following initial treatment, 35% (82/235) received a second course of immunomodulatory therapy.
Treatment-related fluctuations occurred in 5% (53/1,023) of patients, of whom 68% (36/53) underwent re-treatment with intravenous immunoglobulin or plasma exchange.

Cite This Study

Verboon et al. (2019) studied this question.

synapsesocial.com/papers/6a747518f2cd31a1fadbd4fc https://doi.org/10.1212/wnl.0000000000007719

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark